Long-term effects of irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: An irbesartan in patients with type 2 diabetes and microalbuminuria (IRMA 2) substudy

Diabetes Care

Volumn 34, Issue 5, 2011, Pages 1192-1198

  Broedbaek, Kasper ^a,b   Henriksen, Trine ^a,b   Weimann, Allan ^a,b   Petersen, Morten ^a,b   Andersen, Jon T ^a,b   Afzal, Shoaib ^a,b   Jimenez Solem, Espen ^a,b   Persson, Frederik ^c   Parving, Hans Henrik ^a,d,e   Rossing, Peter ^c   Poulsen, Henrik E ^a,b,e  

^a Rigshospitalet   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c STENO DIABETES CENTER   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; DNA; HEMOGLOBIN A1C; IRBESARTAN; PLACEBO; RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA OXIDATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LONG TERM CARE; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEIC ACID METABOLISM; RANDOMIZED CONTROLLED TRIAL; RNA OXIDATION; SMOKING; URINARY EXCRETION; URINE LEVEL;

AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEIC ACIDS; OXIDATION-REDUCTION; SMOKING; TETRAZOLES; TREATMENT OUTCOME;

EID: 79956149600     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-2214     Document Type: Article

References (25)

1. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000;355:253-259
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153
3. Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006;47:699-705 (Pubitemid 43740241)
4. Mistry V, Teichert F, Sandhu JK, et al. Non-invasive assessment of oxidatively damaged DNA: liquid chromatography-tandem mass spectrometry analysis of urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine. Methods Mol Biol 2011;682:279-289
5. Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 2003;26:691-697 (Pubitemid 37258655)
6. Miyashita Y, Saiki A, Endo K, et al. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. J Atheroscler Thromb 2009;16:621-626
7. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878
8. Loft S, Vistisen K, Ewertz M, Tjønneland A, Overvad K, Poulsen HE. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index. Carcinogenesis 1992;13:2241-2247 (Pubitemid 23022963)
9. Priemé H, Loft S, Klarlund M, Grønbaek K, Tønnesen P, Poulsen HE. Effect of smoking cessation on oxidative DNA modification estimated by 8-oxo-7,8-dihydro-29-deoxyguanosine excretion. Carcinogenesis 1998;19:347-351 (Pubitemid 28375431)
10. Biesenbach G, Grafinger P, Janko O, Zazgornik J. Influence of cigarette-smoking on the progression of clinical diabetic nephropathy in type 2 diabetic patients. Clin Nephrol 1997;48:146-150 (Pubitemid 27429599)
11. Ritz E, Ogata H, Orth SR. Smoking: a factor promoting onset and progression of diabetic nephropathy. Diabetes Metab 2000;26(Suppl. 4):54-63 (Pubitemid 30618357)
12. Gambaro G, Bax G, Fusaro M, et al. Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. Diabetes Nutr Metab 2001;14:337-342 (Pubitemid 34071382)
13. Henriksen T, Hillestrøm PR, Poulsen HE, Weimann A. Automated method for the direct analysis of 8-oxo-guanosine and 8-oxo-29-deoxyguanosine in human urine using ultraperformance liquid chromatography and tandem mass spectrometry. Free Radic Biol Med 2009;47:629-635
14. Hinokio Y, Suzuki S, Hirai M, Chiba M, Hirai A, Toyota T. Oxidative DNA damage in diabetes mellitus: its association with diabetic complications. Diabetologia 1999;42:995-998 (Pubitemid 29369608)
15. Goodarzi MT, Navidi AA, Rezaei M, Babahmadi-Rezaei H. Oxidative damage to DNA and lipids: correlation with protein glycation in patients with type 1 diabetes. J Clin Lab Anal 2010;24:72-76
16. Nishikawa T, Sasahara T, Kiritoshi S, et al. Evaluation of urinary 8-hydroxydeoxyguanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 2003;26:1507-1512 (Pubitemid 36929187)
17. Xu GW, Yao QH, Weng QF, Su BL, Zhang X, Xiong JH. Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy patients. J Pharm Biomed Anal 2004;36:101-104 (Pubitemid 39209412)
18. Nishikawa T, Araki E. Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications. Antioxid Redox Signal 2007;9:343-353 (Pubitemid 46150966)
19. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 2005;4:5
20. Viberti G, Wheeldon NM; Micro-Albuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-678 (Pubitemid 34851925)
21. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 2000;49:1399-1408
22. Karalliedde J, Viberti G. Microalbuminuria and cardiovascular risk. Am J Hypertens 2004;17:986-993 (Pubitemid 39361674)
23. Bruno G, Merletti F, Biggeri A, et al. Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2003;26:2150-2155 (Pubitemid 41184267)
24. Nilsson PM, Gudbjörnsdottir S, Eliasson B, Cederholm J; Steering Committee of the Swedish National Diabetes Register. Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes - data from the National Diabetes Register in Sweden. Diabetes Metab 2004;30:261-268
25. Chuahirun T, Simoni J, Hudson C, et al. Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes. Am J Med Sci 2004;327:57-67 (Pubitemid 38220468)